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Abstract: Overexpression of Pim kinases has an oncogenic/pro-survival role in many hematological
and solid cancers. AZD1208 is a pan-Pim kinase inhibitor that has anti-cancer and anti-adipogenic
actions. Here, we investigated the effects of AZD1208 on the growth of 93T449 cells, a differentiated
human liposarcoma cell line. At 20 µM, AZD1208 was cytotoxic (cytostatic) but not apoptotic,
reducing cell survival without DNA fragmentation, caspase activation or increasing cells in the
sub G1 phase; known apoptotic parameters. Notably, AZD1208 reduced phosphorylation of signal
transducer and activator of transcription-3 (STAT-3) in 93T449 cells. STAT-3 inhibition by AG490,
a JAK2/STAT-3 inhibitor similarly reduced cell survival. AZD1208 down-regulated phosphorylation
of mammalian target of rapamycin (mTOR) and ribosomal S6 while up-regulated eukaryotic initiation
factor-2α (eIF-2α). In addition, AZD1208 induced a LKB-1-independent AMPK activation, which was
crucial for its cytostatic effect, as knock-down of AMPK greatly blocked AZD1208s ability to reduce
cell survival. AZD1208 had no effect on expression of two members of Pim kinase family (Pim-1 and
Pim-3) but inhibited phosphorylation of 4EBP-1, a downstream effector of Pim kinases. Importantly,
a central role for Pim-3 in the actions of AZD1208 was confirmed by knock-down, which not only
reduced 93T449 cell survival but also led to the inhibition of 4EBP-1, mTOR, eIF-2α and STAT-3,
along with the activation of AMPK. In summary, this is the first report demonstrating that AZD1208
inhibits growth of liposarcoma cells and that this activity is mediated through Pim-3 kinase, STAT-3,
mTOR, S6 and AMPK expression and phosphorylation pathways.
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1. Introduction
Soft tissue sarcomas are a heterogeneous group of solid malignant tumors having various histologies
and commonly characterized by aggressive characteristics locally and in distant metastases [1,2]. Notably,
13,040 new cases of soft tissue sarcomas have been reported so far in the United States in 2018 [3].
Liposarcoma represents one of the most common subtypes of soft tissue sarcoma and are associated
with considerable morbidity and mortality and a particularly poor prognosis depending on histological
subtype, anatomical location and tumor burden [4–6]. Despite the development and clinical utilization
of new-targeted chemotherapeutic agents, improved radiation targeting and tissue sparing approaches
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and new surgical techniques, unfortunately, only a minimal increase in overall survival of sarcoma
patients has been demonstrated in the last two decades [7]. Thus, there still remains a great need for
more effective and non-toxic therapeutics to enhance locoregional disease control as well as overall
survival in sarcoma patients.
The provirus integration site for moloney murine leukemia virus (Pim) kinases, composing of
Pim-1, Pim-2 and Pim-3, are active serine (S)/threonine (T) kinases which are highly homologous
with overlapping functions and substrate specificities [8]. They modulate the activity of a variety of
downstream effector proteins, such as, eukaryotic translation initiation factor 4E binding protein-1
(4EBP-1), mammalian target of rapamycin (mTOR), the 40S ribosomal subunit S6 protein, p70 S6 kinase
(p70S6K), signal transducers and activators of transcription-3 (STAT-3), AMP-actuated protein kinase
(AMPK), involved in the control of cell cycle, survival, transcription, translation, drug resistance and
signaling within the microenvironment [8–11]. Unlike other kinases, Pim kinases are constitutively
expressed and activated and tightly controlled. However, there is accumulating evidence that Pim
kinases are overexpressed in many hematological malignancies [12–14] and solid tumors [15,16] and
their overexpression plays a oncogenic/pro-survival role in such tumors. Due to this oncogenic/
pro-survival role in cancer biology, Pim kinases are an emerging target for anti-cancer therapy.
The attribution of oncogenic activity to all three Pim isoforms and the potential for redundancy
argues for the development of inhibitors capable of targeting all family members. Gene knockout
studies also have demonstrated that mice deficient for all three Pim kinases are viable and fertile [17],
which supports the tolerability of pan-Pim kinase inhibition. Pim kinases contain a unique ATP-binding
pocket, which has resulted in the development of highly selective pan-Pim inhibitors such as
AZD1208 [18,19].
AZD1208 is a highly selective and orally available inhibitor for all three members of Pim kinase
family and is known for its anti-cancerous activity in a broad range of cancer cell lines [20–24]. Recently,
we have demonstrated that AZD1208 inhibits adipogenesis of 3T3-L1 adipocytes, addressing its
anti-obesity effect [25]. Interestingly, there is further evidence demonstrating Pim kinases are important
mediators of adipocyte differentiation [26] and considered as a marker of adipocytic differentiation in
adipocytic neoplasm [27]. At present, little is known about the expression and role of Pim kinases in
adipocytic tumors. In this study, we investigated the effects of AZD1208 on the growth of 93T449 cells,
a fully differentiated human adipocytic tumor cell line. Here we report firstly that AZD1208 inhibits
growth of 93T449 cells, which is mediated through Pim kinases regulation of 4EBP-1, STAT-3, mTOR,
S6, eIF-2α and AMPK.
2. Results
2.1. AZD1208 Strongly Inhibits Growth of 93T449 Human Liposarcoma Cells
Initially, we investigated the effects of AZD1208 (Figure 1A) at different concentrations (1, 5,
10 or 20 µM) and times (24, 48 or 72 h) on the growth of 93T449 and SW872 cells by cell number
(Figure 1B) and morphology (Figure 1C). AZD1208 reduced survival of 93T449 and SW872 cells in
a concentration and time-dependent manner (Figure 1). Microscopic observation further revealed
that AZD1208 caused a concentration and time-dependent reduction of 93T449. Next, to see whether
the AZD1208’s growth inhibition is limited to 93T449 cells, we tested the effects of AZD1208 on the
growth of SW872 cells, another human liposarcoma cell line. AZD1208 also caused a concentration-
and time-dependent decrease in the survival of SW872 cells. These results verify that the observed
response to AZD1208 is not cell line dependent. Because of stronger growth inhibitory effect on 93T449
at 20 µM, we decided to focus on this concentration of AZD1208 and 93T449 for further studies.
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Figure 1. Effect of AZD1208 on survival of 93T449 and SW872 cells. (A) The chemical structure of 
AZD1208. (B) 93T449 and SW872 cells were treated with AZD1208 or vehicle control (DMSO; 0.1%) 
at the indicated concentrations and for the indicated times. The numbers of surviving cells were 
measured by cell count assay. The cell count assay was performed in triplicate. Data are means ± SE 
of three independent experiments. * p < 0.05 compared to the value of AZD1208 free control at the 
indicated time. (C) 93T449 and SW872 cells were treated with AZD1208 or vehicle control (DMSO) 
for the indicated times. Images of the conditioned cells were obtained by phase contrast microscopy, 
200 ×. Each image is a representative of three independent experiments. 
  
. S cells.
t i ic t c t i f r the indicate ti es.
ll c t assa . The cel count as ay was performed in triplicate. Data are means ±
t i t
i
. Each i age is a representative of t ree i t ri t .
Int. J. Mol. Sci. 2019, 20, 363 4 of 17
2.2. AZD1208 Does Not Induce Apoptosis of 93T449 Human Liposarcoma Cells
Next, we determined whether treatment with AZD1208 at 20 µM induced apoptosis of 93T449
cells. AZD1208 treatment at 20 µM did not cause nuclear DNA fragmentation at 4, 8 or 24 h (Figure 2A)
or an increased accumulation of sub G1 phase cells at 24 h (Figure 2B). Similarly, AZD1208 at 20 µM had
no effect on procaspase-9, pro-caspase-3 or PARP expression or cleavage (Figure 2C), while, treatment
with z-VAD-fmk, a pan-caspase inhibitor [28], did not interfere with the ability of AZD1208 to reduce
survival of 93T449 cells (Figure 2D).
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Figure 2. Effect of AZD1208 on apoptosis of 93T449 cells. (A) 93T449 cells were treated with 
AZD1208 (20 µM) or vehicle control (DMSO) for the times indicated. At each time point, 
extra-nuclear fragmented DNA from the conditioned cells was extracted and analyzed on a 1.7% 
agarose gel. The image is a representative of three independent experiments. (B) 93T449 cells were 
treated with AZD1208 (20 µM) or vehicle control (DMSO) for 24 h. The conditioned cells were 
harvested and subjected to fluorescence-activated cell sorting (FACS) analysis for measuring the 
population of sub G1 phase. The tables represent the fraction of apoptotic cells. (C) 93T449 cells 
were treated with AZD1208 (20 µM) or vehicle control (DMSO) in triplicate experiments for the 
times designated. At each time point, whole cell lysates were prepared and analyzed for 
procaspase-9, procaspase-3, PARP or β-actin expression or cleavage by Western blotting. (D) 93T449 
cells were treated without or with AZD1208 (20 µM) in the absence or presence of the pan-caspase 
inhibitor z-VAD (50 µM) for 48 h, followed measurement of the number of surviving cells by cell 
count assay. The cell count assay was done in triplicate. Data are means ± SE of three independent 
experiments. * p < 0.05 compared to the control at the indicated time. 
2.3. AZD1208 Reduces Phosphorylation of STAT-3 in 93T449 Human Liposarcoma Cells and 
Pharmacological Inhibition of STAT-3 Leads to Reduction of the Cell Survival 
Evidence suggests a role of STAT-3 protein phosphorylation/activation in cancer cell survival 
[29]. We thus sought to explore whether STAT-3 is expressed and phosphorylated in 93T449 cells 
and whether AZD1208 modulates STAT-3 protein expression and phosphorylation in the cells. 
Notably, in the absence of AZD1208 there were substantial expression and phosphorylation of 
STAT-3 in 93T449 cells at the times tested (Figure 3A). However, treatment with AZD1208 greatly 
reduced phosphorylation of STAT-3 without affecting its total protein expression in 93T449 cells. 
The densitometry data of Figure 3A are shown in Figure 3B. Using AG490, a JAK-2/STAT-3 
i 2. Effect of AZD1208 on apoptosis f 93T449 cells. (A) 93T449 cells wer treated with AZD1208
(20 µM) or vehicle control (DMSO) f r he times indicated. At each time point, extra-nuclear fragmented
DNA from the conditioned cells was extracte and analyzed on a 1.7% agarose gel. The image is
representativ of three ind endent experiments. (B) 93T449 cells w re treated with AZD1208
(20 µM) or vehicle control (D SO) for 24 h. The conditioned cells were harvested and subjected to
fluor cence-activat d cell sorting (FACS) analysis for measuring the populat on of sub G1 phas .
The tables represent the fraction of apoptotic cells. (C) 93T449 cells were treated with AZD1208
(20 µM) or vehicle control (DMSO) in triplicate xperiments for the times designat d. At each tim
point, whole cell lysates were prepared and analyzed for proca pas -9, procaspase-3, PARP or β-actin
expre sion or cleavage by Western blotting. (D) 93T449 cells were treated without r with AZD1208
(20 µM) in the absence or p esence of the pan-caspase in ibitor z-VAD (50 µM) for 48 h, followed
measurement of the number of surviving cells by cell count assay. The c ll count assay was done in
triplicate. Data are means ± SE of three indepe dent exp riments. * p < 0.05 compared to the control at
the indicated time.
2.3. AZD1208 Reduces Phosphorylation of STAT-3 in 93T449 Human Liposarcoma Cells and Pharmacological
Inhibition of STAT-3 Leads to Reduction of the Cell Survival
Evidence suggests a role of STAT-3 protein phosphorylation/activation in cancer cell survival [29].
We thus sought to explore whether STAT-3 is expressed and phosphorylated in 93T449 cells and
whether AZD1208 modulates STAT-3 protein expression and phosphorylation in the cells. Notably, in the
absence of AZD1208 there were substantial expression and phosphorylation of STAT-3 in 93T449 cells
at the times tested (Figure 3A). However, treatment with AZD1208 greatly reduced phosphorylation of
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STAT-3 without affecting its total protein expression in 93T449 cells. The densitometry data of Figure 3A
are shown in Figure 3B. Using AG490, a JAK-2/STAT-3 inhibitor, we further determined the role of
reduced STAT-3 phosphorylation (activation) in AZD1208’s growth inhibition of 93T449 cells. Similar
to AZD1208, AG490 at 25 or 50 µM significantly decreased 93T449 cell survival (Figure 3C) and STAT-3
phosphorylation (Figure 3D). Although there seemed to be a slight decrease in T-STAT-3 expression
levels, expression levels of β-actin used as a control for the total proteins loaded remain constant under
these experimental conditions.
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2.4. AZD1208 Inhibits mTOR, S6 and eIF-2α in 93T449 Liposarcoma Cells
ZD1208 inhibits growth of acute myeloid leukemi (AML) cells, in part through inhibition
of mTOR, S6K, S6 and 4E-BP1 [9]. This prompted us to investigate whether AZD1208 affects the
expression and phosphorylation of mTOR, S6 and eIF-2α, translation regulatory proteins, in 93T449
cells. In the absence of AZD1208, there was a time-dependent increase of mTOR phosphorylation in
93T449 cells at the times tested (Figure 4A). Treatment with AZD1208 at 20 µM substantially repressed
mTOR phosphorylation without altering its total expression (Figure 4B). The densitometry data of
Figure 4B are shown in Figure 4C. Interestingly, there was high phosphorylation of S6 in 93T449 cells
at the times tested (Figure 4D). However, treatment with AZD1208 especially at 4 or 24 h resulted in a
strong inhibition of S6 phosphorylation in 93T449 cells. Of further note, in the absence of AZD1208,
there was high phosphorylation of eIF-2α at 4 h but the protein phosphorylation level largely declined
at 8 or 24 h in 93T449 cells. However, treatment with AZD1208 especially at 8 or 24 h led to a significant
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increase of eIF-2α phosphorylation in 93T449 cells. Total protein expression of S6 and eIF-2α were not
largely affected under these experimental conditions. The densitometry data of Figure 4D for S6 and
eIF-2α phosphorylation and expression are shown in Figure 4E.
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S6; T-S6, total S6; p- IF-2α, phosphorylated eIF-2α; T-eIF-2α, total eIF-2α. (E) The densitometry data
of (D). * p < 0.05 compared to the control at the indica ed time.
2.5. AZD1208 Induces Strong Phosphorylation of A PK in 93T449 Cells and A PK Knockdown Greatly
Attenuates Reduction of the Cell Survival by AZD1208
Recently, we demonstrated that AZD1208 induces a strong phosphorylation of AMPK during
the differentiation of 3T3-L1 preadipocytes into adipocytes [25]. We thus investigated whether AMPK
is expressed and phosphorylated in 93T449 cells and whether AZD1208 modulates it. Time course
experiments revealed that there was substantial phosphorylation of AMPK in 93T449 cells at 4 or 8 h
but the protein phosphorylation level largely declined at 24 h. However, at all times tested, treatment
with AZD1208 resulted in strong further phosphorylation of AMPK (Figure 5A). Triplicate experiment
further confirmed that 8 h treatment with AZD1208 significantly up-regulated AMPK phosphorylation
in 93T449 cells (Figure 5B). The densitometry data of Figure 5B are shown in Figure 5C. Using control
or AMPK siRNA transfection, we next determined the role of AMPK activation (phosphorylation) in
AZD1208’s growth inhibitory effect in 93T449 cells. As shown in Figure 5D, there were much lower
protein expression and phosphorylation of AMPK in AMPK siRNA (siAMPK)-transfected 93T449
cells compared with control siRNA (siCon)-transfected ones, showing efficient siAMPK transfection
and knockdown. As shown in Figure 5E, in the absence of AZD1208, there was a slight reduction of
survival of the siAMPK-transfected 93T449 cells compared with siCon-transfected controls. However,
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in the presence of AZD1208, there was a much higher survival of the siAMPK-transfected 93T449 cells
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in triplicate. Data are means ± SE of three inde endent experiments. * p < 0.05 c mpa d to the control
at the indicated time; # p < 0.05 compared to AZD1208 at the indicated time.
2.6. AZD1208-Induced AMPK Phosphorylation in 93T449 Cells Appears to Be Not through LKB-1 But
through Decrease in Cellular ATP Contents
Increasing evid nce suggests tha AMPK phosphorylation is greatly regulated by LKB-1 [30].
We thus investigated whether LKB-1 is expressed and phosphorylated in 93T449 cells and whether
AZD1208 modulates it. In the absence of AZD1208, there were high phosphorylation and expression
of LKB-1 in 93T449 cells at all the times tested (Figure 6A). Interestingly, 4 or 8 h treatment with
AZD1208 further enhanced LKB-1 phosphorylation without affecting its total expression in 93T449
cells. However, AZD1208 treatment at 24 h largely decreased LKB-1 phosphorylation without affecting
its total expression in 93T449 cells. Using control siRNA (siCon) or LKB1 siRNA (siLKB-1) transfection,
we next investigated the role of LKB-1 in AZD1208-induced AMPK phosphorylation in 93T449 cells.
There were much lower expression and phosphorylation of LKB-1 in siLKB-1-transfected 93T449 cells
compared with siCon-transfected ones, showing the siLKB-1 transfection and knockdown efficiency
(Figure 6B). However, in the presence of siLKB-1 knockdown, there still remained a strong AMPK
phosphorylation. Moreover, there was no big difference in AMPK phosphorylation between siCon-
and siAMPK-transfected cells. Given that AMPK activation is also controlled by change in the cellular
AMP/ATP ratio [31], we next determined whether AZD1208 alters the amount of cellular ATP in
93T449 cells. For comparison, 2-deoxyglucose (2-DG) that lowers cellular ATP content [32] was
included as a positive control. As expected, 24 h treatment with 2-DG at 1 mM substantially lowered
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cellular ATP content in 93T449 cells (Figure 6C). Similarly, 8 or 24 h treatment with AZD1208 also
decreased cellular ATP content in the cells.
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prepared and analyzed for p-LKB-1 and T-LKB-1 by Western blotting. p-LKB-1, phosphorylated LKB-1;
T-LKB-1, total LKB-1. The image is a representative of three independent experiments. (B) 93T449
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24 h. Whole cell lysates were prepared and analyzed for T-LKB-1, p-LKB-1, p-AMPK and T-AMPK
by Western blotting. (C) 93T449 cells were treated with AZD1208 (20 µM) or vehicle control for the
times designated. For comparison, cells were treated with 1 mM of deoxyglucose (2-DG), a known ATP
pleting agent for 24 h. At each time point, c llular ATP content was measured by ATP measurement
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2.7. AZD1208 Does Not Affect Expression of Pim Kinases but It Reduces the Phosphorylation of 4EBP-1,
a Downstream Effector of Pim Kinases, in 93T449 Human Liposarcoma Cells
Given that AZD1208 is pan-Pim kinase inhibit r, we next examined whether members of
Pim kinase family are expressed in 93T449 cells and whether AZD1208 (20 µM) modulates their
expression and/or kinase activity. Notably, as shown in Figure 7A, in the absence of AZD1208,
there was substantial expression of Pim-1 and Pim-3 but not Pim-2, in 93T449 cells. The densitometry
data of Figure 7A for Pim-1 and Pim-3 protein expression are shown in Figure 7B. There was also
an enhancement of phosphorylation of 4EBP-1, a known downstream substrate of Pim kinases [33],
in 93T449 cells at all the times tested (Figure 7C). However, treatment with AZD1208 at 20 µM repressed
4EBP-1 phosphorylation in 93T449 cells (Figure 7C,D). The densitometry data of Figure 7D are shown in
Figure 7E. Given that AZD1208 is a low-nanomolar inhibitor of Pim kinase, we further determined the
potential concentration of AZD1208 required to inhibit Pim kinases in 93T449 cells. Of note, treatment
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with AZD1208 at lower concentrations applied (0.01, 0.1 or 1 µM) does not inhibit phosphorylation
of 4EBP-1, whereas the drug treatment at 5, 10 or 20 µM markedly inhibits 4EBP-1 phosphorylation
in 93T449 cells (Figure 7F). Apparently, 20 µM of AZD1208 appeared to maximally inhibit 4EBP-1
phosphorylation in 93T449 cells. These results strongly suggest that the growth inhibition of 93T449
liposarcoma cells by AZD1208 at 20 µM is attributable to Pim kinases inhibition.
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2.8. Pim-3 Knock-Down Causes Not Only Growth Inhibition But Also Alteration of Phosphorylation of
4EBP-1, STAT-3, mTOR, AMPK and eIF-2a in 93T449 Human Liposarcoma Cells
We further probed the role of Pim-3 in AZD1208-induced AMPK phosphorylation in 93T449 cells
using control siRNA (siCon) or Pim-3 siRNA (siPim-3) knockdown. siPim-3-transfection led to an
efficient knockdown of Pim-3 in 93T449 cells compared with siCon-transfected ones (Figure 8A).
Notably, cell count analysis and microscopic observation demonstrated decreased cell survival
in siPim-3-knockdown 93T449 cells compared with siCon-transfected ones (Figure 8B,C), similar
to what we observed with AZD1208 treatments. Additionally and again identical to AZD1208,
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siPim-3-knockdown led to a lower phosphorylation of 4EBP-1, STAT-3 and mTOR and an increased
phosphorylation of AMPK and eIF-2α when compared with siCon-transfected cells (Figure 8D).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 10 of 17 
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3. Discussion
Pim kinases play important roles in proliferation, survival and growth of a number of hematological
and solid cancers, supporting Pim kinases as valid therapeutic targets [8,10,33–35]. Indeed, numerous
Pim kinases inhibitors have shown their anti-cancer property in multiple tumor models in vitro and
in vivo [9,36,37]. AZD1208 is a pan-Pim kinase inhibitor that is known to have potent anti-cancer
activity in blood cancer [9,10] and prostate cancer cells [21]. AZD1208 has yet to be investigated in
adipocytic tumors. In this study, we report for the first time that AZD1208 inhibits the growth of 93T449
human liposarcoma cells through Pim-3, 4EBP-1, mTOR, S6, eIF-2α, STAT-3 and AMPK. We further
provide evidence that Pim-3 is crucial for the growth of 93T449 cells and the phosphorylation (activity)
of 4EBP-1, STAT-3, AMPK, mTOR and eIF-2α.
AZD1208 inhibits proliferation and growth of AML cell lines [9,10] and induces apoptosis in
prostate cancer graft specimens [21]. In the 93T449 human liposarcoma, AZD1208 at 20 µM was highly
cytostatic (cytotoxic) but not apoptotic, as evidenced by cell death with no increase in any apoptotic
marker measured: sub G1 phase, nuclear DNA fragmentation or caspase-9/3 activation. These results
support the notion that AZD1208-mediated growth inhibition in 93T449 cells at 20 µM is not through
classical apoptosis but through regulation of other mechanisms and/or factors.
The family of STATs plays a crucial role in the expression of genes which are involved in cancer
cell survival, proliferation, apoptosis and angiogenesis [29,38,39]. Among the STAT family, STAT-3 has
been extensively studied due to its constitutive expression in many human cancers including soft tissue
sarcoma cells [40–42]. Importantly, mounting evidence indicates that STAT-3 activation contributes
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to proliferation and oncogenesis by modulating the expression of a variety of genes required for
tumor cell survival, proliferation and angiogenesis, as well as invasion and metastasis [43] but STAT-3
inhibition leads to suppression of the growth of numerous cancers in vitro and in vivo [29,44,45]. It is
thus suggested that targeted disruption of STAT-3 could be one potential approach to treat human
cancers overexpressing STAT-3 [46]. Until now, little is known about the phosphorylation of STAT-3
and AZD1208 regulation of the STAT-3 phosphorylation in human liposarcoma cells. In this study,
STAT-3 was highly phosphorylated in 93T449 cells and AZD1208 at 20 µM greatly inhibited this
STAT-3 phosphorylation. In addition, pharmacological inhibition of STAT-3 by AG490, a JAK2/STAT-3
inhibitor, leads to partial growth inhibition of 93T449 cells. These results suggest that STAT-3 activity
is necessary for the survival of 93T449 cells and that STAT-3 inhibition contributes to the growth
inhibition effects of AZD1208 at 20 µM in 93T449 cells.
AZD1208 inhibits phosphorylation of 4EBP1, p70S6K and S6 and suppresses translation in
MOLM-16 AML cells [18]. Of further note, there is a recent study demonstrating that AZD1208
suppresses mTOR signaling, including inhibition of phosphorylation of mTOR (S2448), p70S6K (T389),
S6 (S235/236) and 4EBP-1 (S65), in AML cell lines, which contribute to AZD1208’s cytostatic effects [9].
Moreover, there is further evidence that Pim kinases regulate mTOR activity [47]. mTOR, S6K, S6 and
4EBP-1 are key proteins involved in translation [9]. Accordingly, mTOR regulates protein synthesis by
hyperphosphorylating 4EBP-1, which decreases its affinity for the translation initiation factor eIF4E [48]
and phosphorylating and activating p70S6K, which in turn phosphorylates the 40S ribosomal subunit
S6 protein [49]. We showed in this study that AZD1208 at 20 µM does not alter expression of Pim-1/3
but it greatly inhibits phosphorylation of mTOR, S6 and 4EBP-1 in 93T449 cells, suggesting that the
AZD1208’s cytostatic effect in 93T449 cells at 20 µM is attributable to by inhibition of mTOR, S6 and
4EBP-1 proteins, thereby leading to suppression of translation in 93T449 cells. A notable finding of
the present study is AZD1208 regulation of eIF-2α protein. Accordingly, eIF-2α is phosphorylated in
response to cellular stress and its phosphorylation leads to global translation inhibition by suppressing
the formation of ternary complex (eIF2-GTP-Met-tRNA) in translation initiation [50]. Thus considering
that AZD1208 largely up-regulates eIF-2α phosphorylation in 93T449 cells, it is conceivable that the
AZD1208-induced eIF-2α phosphorylation will further interfere with translation initiation in 93T449
cells, which would facilitate the drug’s cytostatic effect.
AMPK is a key regulator of energy metabolism and balance [51]. It is a heterotrimeric protein
kinase consisting of a catalytic α subunit and regulatory β and γ subunits. Mounting evidence strongly
suggests that AMPK activation leads to cell cycle arrest and growth inhibition in several tumor
cells [10,52–55]. Interestingly, the Pim-mediated regulation of AMPK activity has been previously
proposed, with the facts that a Pim kinase inhibitor SMI-4a induces activation of AMPK via increased
AMP/ATP ratio in mouse embryonic fibroblasts [10]. Recently, we also have demonstrated the ability
of AZD1208 to induce strong AMPK phosphorylation in 3T3-L1 preadipocytes [25]. At present, little
is known about AZD1208 regulation of AMPK in liposarcoma cells. Strikingly, we observed that
AZD1208 at 20 µM greatly increases AMPK phosphorylation in 93T449 cells and knock-down of
AMPK largely attenuates the ability of AZD1208 to inhibit growth of 93T449 cells. These results
strongly indicate that the AZD1208’s cytostatic effect on 93T449 cells is largely due to AMPK activation.
It is documented that AMPK phosphorylation is controlled by upstream kinases, such as LKB-1 [30]
and change in cellular ATP content [31]. Our findings showed that AMPK activation by AZD1208 in
93T449 cells was LKB-1-independent but linked rather to a reduced cellular ATP content. Cellular
expression of Pim kinases is regulated at multiple stages, including transcription, post-transcription
and translation [8]. Because Pim kinases are constitutively expressed and active with very short
protein half-life (<5 min), it is suggested that regulation of the protein stability is critical for their
cellular function and activity [56]. It is of interest that only Pim-1 and Pim-3 but not Pim-2, were highly
expressed in 93T449 cells. These results suggest 93T449 cells contain unique regulatory systems/factors
that selectively lead to high protein expression and/or stability of Pim-1 and Pim-3. AZD1208 at 20
µM did not affect expression of Pim-1 and Pim-3 but strongly reduced phosphorylation of 4EBP-1,
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a well-characterized downstream substrate of Pim kinases in 93T449 cells. Further considering that,
the 1 µM concentration of AZD1208 inhibiting cell growth does not inhibit phosphorylation of 4EBP-1
in 93T449 cells. The cytostatic response of 93T449 cells to AZD1208 at 20 µM appears to be in part
attributable to Pim kinases inhibition and also mediated via inhibition of several off-targets, such as
STAT-3, AMPK, mTOR and eIF-2α herein. As of now, little is known about the role of Pim kinases
in liposarcoma. Here we demonstrated that Pim-3 expression and activity are crucial for not only
the growth of 93T449 cells but also the phosphorylation (activity) of mTOR, 4EBP-1, eIF-2α, STAT-3
and AMPK, given that knockdown of Pim-3 leads to growth inhibition of 93T449 cells, decrease in
phosphorylation of 4EBP-1, STAT-3 and mTOR but increase in phosphorylation of AMPK and eIF-2α
in the cells. It further suggests that Pim-3 lies upstream of mTOR, 4EBP-1, eIF-2α, STAT-3 and AMPK
in 93T449 cells.
In summary, this is the first study reporting that AZD1208 has a cytostatic effect in human
liposarcoma cells, which is be mediated through control of the expression and/or phosphorylation of
Pim kinases, 4EBP-1, mTOR, S6, eIF-2α, STAT-3 and AMPK. Although there are still important issues
that remain to be resolved, including anti-tumor effect of AZD1208 on animal models, the present
findings support that AZD1208 is a potential therapeutics for the treatment of liposarcoma.
4. Materials and Methods
4.1. Chemicals and Antibodies
AZD1208 was purchased from Selleckchem (Houston, TX, USA). RPMI-1640 (LM011-01), DMEM
(LM001-05), fetal bovine serum (FBS) (S001-01) and cocktail of penicillin/streptomycin antibiotics
(LS202-02) were obtained from WelGENE (Daegu, Korea). Anti-procaspase-9 (ADI-AAM-139) and
anti-procaspase-3 (ADI-AAP-113) antibodies were bought from Enzo (Farmingdale, NY, USA).
Anti-PARP (11835238001) antibody was obtained from Roche Diagnostics (Mannheim, Germany).
Anti-actin (A5441) antibody was purchased from Sigma (St. Louis, MO, USA). Anti-phospho(p)-4EBP-1
(S65) (#9455), anti-4EBP-1 (#9452), anti-p-S6 (S235/236) (#2211), anti-S6 (#2317), anti-p-mTOR (S2448)
(#5536), anti-mTOR (#2972), anti-p-AMPK (T172) (#2535), anti-AMPK (#2793), anti-p-LKB-1 (S428)
(#3482), anti-LKB-1(#3047) and anti-eIF-2α (#9722), antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). Anti-p-eIF-2α (S51) (ab32157) antibody was bought from Abcam
(Cambridge, MA, USA). Anti-Pim-1 (sc-374116), anti-Pim-3 (sc-98959), anti-p-STAT-3 (Tyr(Y)705)
(sc-8059), anti-STAT-3 (sc-8019), secondary goat anti-Rabbit and goat anti-Mouse IgG antibodies,
control siRNA (sc-37007), AMPK siRNA (sc-45312), LKB-1 siRNA (sc-35816) and Pim-3 siRNA
(sc-61353) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA). z-VAD-fmk and
AG490 were purchased from Calbiochem (Madison, WI, USA). Super Signal™ West Pico PLUS
Enhanced chemiluminescence (ECL, #34080) was purchased from Thermo Scientific (Waltham, MA,
USA). Plasticwares: 6-well and 24-well plates and 60 and 100 mm of cell culture dish were obtained
from SPL Life Sciences (Gyeonggi-do, Korea).
4.2. Cell Culture
Human 93T449 (CRL-3043™) and SW872 (CRL-HTB92™) liposarcoma cells (ATCC; Manassas,
VA, USA) were grown in RPMI 1640/DMEM media supplemented with 10% heat-inactivated FBS
(HI-FBS) and 1% penicillin/streptomycin at 37 ◦C in a humidified condition of 95% air and 5% CO2.
4.3. Cell Count Assay and Cell Morphology Analysis
93T449 and SW872 cells were seeded in a 24-well plate (0.5 × 105 cells/500 µL/well) overnight.
Cells were treated without or with AZD1208 or other agents (AG490, z-VAD-fmk) at the indicated
concentrations and for the times designated. At each time point, the number of surviving cells,
which cannot be stained with trypan blue dye, was counted using phase contrast microscope.
Approximately 50 cells were counted for each evaluation. The cell count assay was performed
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in triplicate. Data are means ± standard errors (SE) of three independent experiments. Survival is
expressed as a percentage of control. For cell morphology analysis, phase contrast images of the
conditioned cells treated with AZD1208 or transfected with siRNA (control, Pim-3) were taken with a
compound microscope (Nikon Eclipse TS200, Nikon Corp., Tokyo, Japan).
4.4. Measurement of DNA Fragmentation
Measurement of DNA fragmentation was conducted as mentioned in our previous study [57].
Briefly, 93T449 cells were seeded at a density of (2× 105 cells/mL) the day before treatment. Cells were
treated with AZD1208 (20 µM) or vehicle control (DMSO) for 4, 8 or 24 h. At each time point,
the conditioned cells were harvested, washed and lysed in a buffer [50 mM Tris (pH 8.0), 0.5%
sarkosyl, 0.5 mg/mL proteinase K and 1 mM EDTA] at 55 ◦C for 3 h, followed by the addition of
RNase A (0.5 µg/mL) and incubation at 55 ◦C for 18 h. The lysate was centrifuged at 10,000× g for
20 min. Genomic DNA was extracted with equal volume of neutral phenol-chloroform-isoamyl alcohol
mixture (25:24:1) and analyzed by electrophoresis on a 1.8% agarose gel. The DNA was visualized
and photographed under UV illumination after staining with ethidium bromide (0.1 µg/mL) by Gel
documentation system (Gel Doc-XR, Bio-rad, Hercules, CA, USA).
4.5. Measurement of the Population of Sub G1 Phase by Flow Cytometry Analysis
After 24 h treatment with vehicle control (DMSO) or AZD1208 (20 µM), 93T449 cells were
harvested and washed with PBS, fixed in ice-cold 70% ethanol and stored at 4 ◦C. Prior to analysis, cells
were again washed once with PBS, suspended in 1 mL of cold propidium iodide solution containing
100 µg/mL RNase A, 50 µg/mL propidium iodide, 0.1% (w/v) sodium citrate and 0.1% (v/v) NP-40
and further incubated on ice for 30 min in the darkness. Cytometric analyses were carried out with a
flow cytometer (FACS Caliber, Becton Dikinson, MD, USA) and CellQuest software. Approximately,
10,000 cells were counted for the analysis.
4.6. Preparation of Whole Cell Lysates
93T449 cells were seeded in 6-well plates the day before treatment. Cells were treated with
AZD1208 (20 µM) and/or other reagents or vehicle control (DMSO) for the indicated times. At each
time point, cells were washed twice with PBS and proteins were extracted using modified RIPA buffer
[50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.25% sodium deoxycholate,
1% Triton X-100, 1% Nonidet P-40, 1 mM EDTA, 1 mM EGTA, proteinase inhibitor cocktail (1X)].
The cell lysates were collected and centrifuged at 12,000 rpm for 20 min at 4 ◦C. The supernatant was
saved and its protein concentration was determined by bicinchoninic acid assay (BCA) Protein Assay
Kit (Thermo scientific, Rockford, IL, USA).
4.7. Immunoblot Analysis
An equal amount of proteins (50 µg) was separated by SDS-PAGE and transferred onto
polyvinyldenefluoride (PVDF) membrane (Millipore; Billerica, MA, USA) by electroplating.
The membranes were washed with Tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl, pH 7.5)
supplemented with 0.05% (v/v) Tween 20 (TBS-T) followed by blocking with TBS-T containing 5% (w/v)
non-fat dried milk. The membranes were probed overnight with antibodies specific for the protein of
interest at 4 ◦C, followed by incubating with secondary antibodies coupled to horseradish peroxidase
at room temperature for 2 h. The membranes were washed and immune-reactivities were detected
by Super Signal™ West Pico PLUS enhanced chemiluminescence (ECL) according to manufacturer
(Thermo Scientific, Waltham, MA, USA). Equal protein loading was assessed by the expression levels
of β-actin.
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4.8. Small Interfering RNA (siRNA) Transfection
93T449 cells (1 × 105 cells/mL) were seeded into 6-well plates and transfected for 6 h with
100 picomole (pM) of control, AMPK, LKB-1 or Pim-3 siRNA using Lipofectamine® RNAiMAX
Transfection Reagent (Invitrogen, Waltham, MA, USA). Culture media from the conditioned cells
were removed and refreshed with RPMI-1640 containing 10% HI-FBS, followed by incubation for
18 h. After 24 h post-transfection, the conditioned cells were treated with or without AZD1208 for
the designated times. The numbers of surviving cells, which cannot be stained with trypan blue dye,
were counted under microscope. The cell count assay was done in triplicates. Data are means ± SE of
three independent experiments. Whole cell lysates were also prepared from the conditioned cells and
analyzed for Western blotting.
4.9. Measurement of Cellular ATP Contents
93T449 cells (0.3 × 105 cell per well) were seeded in 96 well-plates and treated without or
with AZD1208 (20 µM) or 2-deoxyglucose (2-DG), a glucose mimetic that depletes levels of cellular
ATP, for the indicated times and doses. At each time point, cellular ATP levels were measured by
luciferase activity using a luminescence assay kit according to the manufacturer’s protocol (#6016941,
ATPLite-1step, Perkin Elmer Inc., Waltham, MA, USA). After 2 min incubation, luminescence was
measured on a Victor (Perkin Elmer).
4.10. Statistical Analyses
Cell count analysis was performed in triplicates and repeated three times. Data were expressed
as mean ± SE. The significance of difference was determined by One-Way ANOVA (Laerd Statistics,
Chicago, IL, USA). All significance testing was based upon a p < 0.05.
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